XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Current Assets:    
Cash and cash equivalents $ 12,559,607 $ 26,480,928
Prepaid expenses 9,014,124 7,889,506
Total Current Assets 21,573,731 34,370,434
Property and equipment, net 275 1,432
Operating lease right-of-use asset, net 352,505 454,426
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Assets 90,711,369 103,611,150
Current Liabilities:    
Accounts payable 2,669,507 2,927,334
Accrued expenses 151,204 476,300
Accrued compensation 1,123,076 2,156,983
Operating lease liability 229,733 218,380
Total Current Liabilities 4,173,520 5,778,997
Deferred tax liability 6,425,800 6,137,800
Operating lease liability – noncurrent 145,098 262,865
Total Liabilities 10,744,418 12,179,662
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 159,094,781 and 158,857,798 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively 159,095 158,858
Additional paid-in capital 259,214,194 252,903,629
Accumulated deficit (180,006,718) (162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 79,366,571 90,831,108
Non-controlling interest 600,380 600,380
Total Equity 79,966,951 91,431,488
Total Liabilities and Equity $ 90,711,369 $ 103,611,150